Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 19, Issue 5, 2018, Pages 603-615

  Dummer, Reinhard ^a   Ascierto, Paolo A ^b   Gogas, Helen J ^c   Arance, Ana ^d   Mandala, Mario ^e   Liszkay, Gabriella ^f   Garbe, Claus ^g   Schadendorf, Dirk ^h,i   Krajsova, Ivana ^j   Gutzmer, Ralf ^k   Chiarion Sileni, Vanna ^l   Dutriaux, Caroline ^m   de Groot, Jan Willem B ⁿ   Yamazaki, Naoya ^o   Loquai, Carmen ^p   Moutouh de Parseval, Laure A ^q   Pickard, Michael D ^r   Sandor, Victor ^r   Robert, Caroline ^s   Flaherty, Keith T ^t  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF ATHENS   (Greece)

^d HOSPITAL CLÍNIC   (Spain)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j CHARLES UNIVERSITY   (Czech Republic)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^m HÔPITAL SAINT ANDRÉ   (France)

ⁿ Department of Medical Oncology ^*  (Netherlands)

^o NATIONAL CANCER CENTER HOSPITAL   (Japan)

^p UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^q NOVARTIS PHARMA AG   (Switzerland)

^r ARRAY BIOPHARMA INC   (United States)

^s INSTITUT GUSTAVE ROUSSY   (France)

^t MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BINIMETINIB; CREATINE KINASE; ENCORAFENIB; GAMMA GLUTAMYLTRANSFERASE; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BENZIMIDAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; CARBAMIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TUMOR MARKER;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DARIER DISEASE; DEATH; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; ERYTHEMA; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERKERATOSIS; HYPERTENSION; INSOMNIA; KERATOACANTHOMA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PAIN; PALMOPLANTAR KERATODERMA; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK REDUCTION; SIDE EFFECT; SKIN PAPILLOMA; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; SKIN TUMOR; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BIOMARKERS, TUMOR; CARBAMATES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PROGRESSION-FREE SURVIVAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; VEMURAFENIB; YOUNG ADULT;

EID: 85044302834     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30142-6     Document Type: Article

References (31)

1. Krauthammer, M, Kong, Y, Bacchiocchi, A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 47 (2015), 996–1002.
2. Solit, DB, Garraway, LA, Pratilas, CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006), 358–362.
3. Chapman, PB, Hauschild, A, Robert, C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
4. Tsai, J, Lee, JT, Wang, W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105 (2008), 3041–3046.
5. Hauschild, A, Grob, JJ, Demidov, LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
6. Sullivan, RJ, Flaherty, KT, New strategies in melanoma: entering the era of combinatorial therapy. Clin Cancer Res 21 (2015), 2424–2435.
7. Poulikakos, PI, Zhang, C, Bollag, G, Shokat, KM, Rosen, N, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464 (2010), 427–430.
8. Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
9. Robert, C, Karaszewska, B, Schachter, J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
10. Ascierto, PA, McArthur, GA, Dreno, B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17 (2016), 1248–1260.
11. Flaherty, KT, Robert, C, Hersey, P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367 (2012), 107–114.
12. Dummer, R, Hauschild, A, Lindenblatt, N, Pentheroudakis, G, Keilholz, U, Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:suppl 5 (2015), v126–v132.
13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology, melanoma version 2.2018. 2018, National Comprehensive Cancer Network, Fort Washington, PA.
14. Larkin, J, Ascierto, PA, Dreno, B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371 (2014), 1867–1876.
15. Long, GV, Stroyakovsky, DL, Gogas, H, et al. COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol, 32(suppl 15), 2014, 9011.
16. Robert, C, Karaszewska, B, Schachter, J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Ann Oncol 27 (2016), 1–36.
17. Long, GV, Stroyakovskiy, D, Gogas, H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371 (2014), 1877–1888.
18. Delord, JP, Robert, C, Nyakas, M, et al. Phase I dose-escalation and expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res 23 (2017), 5339–5348.
19. Adelmann, CH, Ching, G, Du, L, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget 7 (2016), 30453–30460.
20. Ascierto, PA, Schadendorf, D, Berking, C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14 (2013), 249–256.
21. Dummer, R, Sandhu, S, Hassel, JC, et al. LOGIC2: phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. Eur J Cancer 51 (2015), S667–S668.
22. Sullivan, RJ, Weber, JS, Patel, SP, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol, 33, 2015, 9007.
23. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
24. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2010, National Cancer Institute https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed March 15, 2018).
25. McArthur, GA, Chapman, PB, Robert, C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15 (2014), 323–332.
26. Sosman, JA, Kim, KB, Schuchter, L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366 (2012), 707–714.
27. Larkin, J, Del Vecchio, M, Ascierto, PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15 (2014), 436–444.
28. Novartis Pharmaceuticals Corporation. TAFINLAR (dabrafenib). Full prescribing information. 2017, Novartis Pharmaceuticals Corporation, East Hanover, NJ https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tafinlar.pdf (accessed March 12, 2018).
29. Long, GV, Flaherty, KT, Stroyakovskiy, D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28 (2017), 1631–1639.
30. Dummer, R, Rinderknecht, J, Goldinger, SM, Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 366 (2012), 480–481.
31. Genentech, USA, Cotellic (cobimetinib). Full Prescribing Information. 2016, Genentech USA, South San Francisco, CA https://www.gene.com/download/pdf/cotellic_prescribing.pdf (accessed Jan 25, 2018).